Name | Mepazine |
Description | Mepazine (Pecazine) is a potent and selective inhibitor of MALT1, inhibiting GSTMALT1 full length and GSTMALT1 325-760 with IC50s of 0.83 μM and 0.42 μM, respectively. Mepazine enhances apoptosis and impacts cell viability. |
In vitro | Mepazine (5, 10, and 20 μM) decreases cell viability in the ABC-DLBCL cells HBL1, OCI-Ly3, U2932, and TMD8, without significantly affecting GCB-DLBCL cells[1]. |
In vivo | In female NSG mice with a murine DLBCL xenogeneic tumor model, Mepazine (16 mg/kg; i.p.) interferes with the growth and induces apoptosis of ABC-DLBCL cell line OCI-Ly10. Mepazine strongly impairs the expansion of OCI-Ly10 with daily administration[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 25 mg/mL (80.53 mM)
|
Keywords | diffuse | B cell | inhibit | large | mucosa associated lymphoid tissue lymphoma translocation gene 1 | MALT1 | lymphoma | Mepazine | ABC-DLBCL | Apoptosis | Inhibitor |
Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin |
Related Compound Libraries | NF-κB Signaling Compound Library | Bioactive Compound Library | ReFRAME Related Library | Drug-induced Liver Injury (DILI) Compound Library | Inhibitor Library | Bioactive Compounds Library Max |